Boston Scientific’s Watchman device, designed to prevent stroke by closing off the left atrial appendage in the heart, has recently come under scrutiny after the FDA flagged safety concerns linked to its use. As of July30, 2025, Boston Scientific has reported 120 serious injuries and 17 fatalities associated with issues related to the Watchman Access System used in the implantation procedure. The company and FDA issued early alerts and have updated the instructions for use, targeting how the device is implanted—especially in relation to anesthesia and patient selection—to help mitigate risk.

While Boston Scientific’s internal investigations suggest the issue is not tied to the device’s design or manufacturing, this high-profile incident is expected to significantly impact the structural heart occlusion market, which relies on innovation, safety, and clinician confidence. The Watchman is a market leader in the left atrial appendage closure (LAAC) segment. The increased scrutiny, reported injuries and deaths, and the subsequent FDA communications may:

Lead to heightened caution or delays in device adoption among hospitals and physicians.

Increase regulatory scrutiny and post-market surveillance for LAAC and similar structural heart implants industry-wide.

Create opportunities for competitive devices and alternative therapies if customers seek options perceived as safer or requiring less procedural complexity.

Affect Boston Scientific’s market share and revenue—structural heart implants are among their largest business lines, and share prices dipped following the announcements.

Drive further innovation as manufacturers seek to regain trust and improve device safety and usability.

Device manufacturers, healthcare systems, and clinicians will be closely monitoring post-market data and awaiting longer-term guidance from regulators. The focus on patient safety and procedural protocols is likely to shape the trajectory of the entire structural heart occlusion sector in the months ahead.